NOAC Portuguese Real World Study

Exclusion Criteria

• •Specialty of the physician responsible for the OAC prescription in the index date is one of the following: orthopedics, general surgery, vascular surgery or any other surgical specialty;
• •Duration of OAC therapy during follow-up inferior to the cut-off defined during the feasibility assessment (except if the patient was admitted to in-hospital care during follow-up);
• •The OAC dispensed in the index date was one of the following: dabigatran 75 mg or rivaroxaban 10 mg
• •Hospital claims lacking a diagnosis code indicative of AF during the study period;
• •Hospital claim indicating a diagnosis or procedure code indicative of pregnancy or childbirth during the study period;
• •Hospital claim indicating a diagnosis or procedure code indicative of valvular heart disease, venous thromboembolism, cardiac surgery, pericarditis, hyperthyroidism and thyrotoxicity during the baseline period;
• •Hospital claim indicating a diagnosis or procedure code indicative of hip and knee replacement surgery during the 6 weeks prior to the index date. Patients with past use of OAC will be excluded. Therefore, patients meeting any of the following criteria will be excluded:
• •Had any OAC (apixaban, dabigatran, edoxaban, rivaroxaban, VKAs) dispensed during the 12-month baseline period;
• •Had \>1 OAC dispensed on the index date.